Lymphocytic Leukemia Clinical Trial
Official title:
A Randomized Phase 3 Study of Fludarabine and Rituximab With or Without Genasense® (Oblimersen Sodium) in Previously Untreated Subjects With Chronic Lymphocytic Leukemia
To compare the efficacy and safety of combination treatment with Genasense, fludarabine, and rituximab versus combination treatment with fludarabine and rituximab in previously untreated subjects with CLL.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00609869 -
Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab
|
Phase 2 | |
Active, not recruiting |
NCT05065866 -
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
|
Phase 1 | |
Completed |
NCT00013533 -
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
|
Early Phase 1 | |
Completed |
NCT02481297 -
Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
|
Phase 2 | |
Completed |
NCT02434484 -
Symbenda Post-Marketing Surveillance (PMS)
|
||
Completed |
NCT02556892 -
A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
|
Phase 1 | |
Completed |
NCT00935792 -
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT02885038 -
Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies
|
N/A | |
Completed |
NCT01499147 -
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
|
N/A | |
Recruiting |
NCT03219450 -
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
|
Phase 1 | |
Recruiting |
NCT05272813 -
A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL
|
Phase 1/Phase 2 |